🔴 Beam Therapeutics is trading 4.1% down today after Q2 earnings miss and BofA price target trim

Beam Therapeutics is trading 4.1% down at $27.20 as investors digest a Q2 earnings miss and a price target reduction from Bank of America.

• The decline follows a 9.4% jump in the previous session, suggesting profit-taking as the market weighs disappointing revenue and EPS against an extended cash runway into mid-2029.
• While the broader biotech sector is trading higher, Beam is underperforming as sentiment remains cautious following the mixed financial results.
• Management is pivoting focus toward the BEAM-302 pivotal trial, which remains a key catalyst for the company's clinical pipeline.